OSR Holdings Inc (OSRH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, OSR Holdings Inc (OSRH) has a cash flow conversion efficiency ratio of -0.008x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.07 Million) by net assets ($127.04 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See OSRH net asset quality score to measure how much of total assets are equity-financed.
OSR Holdings Inc - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how OSR Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check OSRH operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
OSR Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OSR Holdings Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
iRobot Corporation
NASDAQ:IRBT
|
1.770x |
|
Zelan Bhd
KLSE:2283
|
-0.111x |
|
Diamyd Medical AB (publ)
ST:DMYD-B
|
-0.233x |
|
PeterLabs Holdings Bhd
KLSE:0171
|
0.107x |
|
Biovica International AB (publ)
ST:BIOVIC-B
|
-0.670x |
|
IntegraFin Holdings plc
LSE:IHP
|
0.599x |
|
Yuyu Pharma Inc
KO:000225
|
0.021x |
|
Office Properties Income Trust
NASDAQ:OPI
|
0.030x |
Annual Cash Flow Conversion Efficiency for OSR Holdings Inc (2020–2025)
The table below shows the annual cash flow conversion efficiency of OSR Holdings Inc from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see OSRH market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $127.04 Million | $-4.33 Million | -0.034x | -110.10% |
| 2024-12-31 | $-6.49 Million | $-2.19 Million | 0.337x | +1439.86% |
| 2023-12-31 | $32.52 Million | $-818.77K | -0.025x | -383.70% |
| 2022-12-31 | $78.77K | $-410.00 | -0.005x | -102.39% |
| 2021-12-31 | $-2.12K | $-461.00 | 0.217x | +101.08% |
| 2020-12-31 | $1.19K | $-23.81K | -20.044x | -- |
About OSR Holdings Inc
OSR Holdings, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Germany, Switzerland, and South Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the… Read more